Our consulting services primarily support pharmaceutical asset development teams, operating as a “plug and play” companion diagnostic group helping to optimize commercial planning for successful launch of personalized medicines. Our focus is on helping these asset development teams create comprehensive commercial plans – designed to drive optimal adoption of companion and other diagnostic tests.
Our work and standardized approach to personalized medicine development ensures that teams consider and address the impact of decisions in all key functional areas – such as technology, regulatory, partners, market access and labs among others – while at the same time ensuring resources are optimally apportioned and allocated. By mirroring the drug development process with which the asset team is completely familiar, uptake of these programs is rapid and integration of personalized medicine specific concepts quickly provides sound, reasoned, analytical metrics on which test commercialization are optimized.
Diaceutics main commercialization programs – Foundation and Alignment – help pharmaceutical teams standardize the planning, analytical and action steps needed to align the co-development of companion and other diagnostic tests with drugs and create a comprehensive commercial plan designed to optimize adoption and therapy goals. These programs help drive better decisions based on actual evidence and case studies and robust metrics improve return on investment – delivering a true competitive and financial advantage.
Proven Process: Developed over the course of six years during real world engagements with top pharmaceutical companies on over 25 personalized medicine projects.
Superior NPV Returns: More confident decisions with higher ROI and decreased risk – aligning overall strategy with necessary technology, regulatory, partnering and launch plans.
Click here to learn more about our Foundation and Alignment programs.
